Skip Navigation


Alcohol and Alcoholism Advance Access originally published online on October 31, 2005
Alcohol and Alcoholism 2006 41(1):11-13; doi:10.1093/alcalc/agh228
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
41/1/11    most recent
agh228v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by KÄHKÖNEN, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KÄHKÖNEN, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author 2005. Published by Oxford University Press on behalf of the Medical Council on Alcohol. All rights reserved

COMMENTARY

RESPONSES TO CARDIOVASCULAR DRUGS DURING ALCOHOL WITHDRAWAL

SEPPO KÄHKÖNEN*

BioMag Laboratory, Helsinki University Central Hospital; Cognitive Brain Research Unit, University of Helsinki, Finland

* Correspondence: Tel.: +358 9 47175579; Fax: +358 9 47175781; E-mail: seppo.kahkonen{at}helsinki.fi

(Received 11 May 2005; first review notified 6 July 2005; in revised form 23 August 2005; accepted 7 October 2005)

Aim: To present findings on the kinetics and dynamics of cardiovascular drugs during alcohol withdrawal (AW), compared with that observed in remission. Method: Studies were reviewed and summarized. Results: A single-dose study in alcoholic patients with propranolol, a ß-adrenergic antagonist, showed that the negative inotropic effect was decreased and the bradycardiac effect increased during AW as compared with during early remission. The hypotensive effect of isosorbid dinitrate, commonly used as a vasodilatator, was weaker at the onset of AW, being associated with the decreased bioavailability of the drug. Verapamil, which is a L-type Ca2+ channel antagonist, produced a bradycardiac effect at the onset of AW, but no effect was observed in early remission. The effect was probably due to changes in L-type Ca2+ channels because no differences in verapamil concentrations between AW and early remission were observed. Conclusion: Taken together, AW modifies the dynamics and kinetics of cardiac drugs, which may have an impact on the treatment of alcoholic patients with cardiac diseases.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A McKeon, M A Frye, and N. Delanty
The alcohol withdrawal syndrome
J. Neurol. Neurosurg. Psychiatry, August 1, 2008; 79(8): 854 - 862.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.